HC Wainwright reiterated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research report sent to investors on Friday, March 29th, AnalystRatings.com reports. They currently have a $32.00 target price on the stock.
“Valuation and risks to price target achievement. We reiterate our Buy rating and $32 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our model currently received the majority of valuation contribution from KB103 for the treatment of DEB patients, with modest contribution from KB105 for ARCI.”,” HC Wainwright’s analyst wrote.
A number of other equities analysts have also issued reports on the stock. Zacks Investment Research upgraded shares of Krystal Biotech from a hold rating to a buy rating and set a $26.00 target price for the company in a research report on Thursday, December 20th. Chardan Capital increased their target price on shares of Krystal Biotech from $50.00 to $57.50 and gave the company a buy rating in a research report on Tuesday, March 12th. Cowen assumed coverage on shares of Krystal Biotech in a research report on Wednesday, December 12th. They issued an outperform rating for the company. Cantor Fitzgerald reiterated a buy rating and issued a $34.00 target price on shares of Krystal Biotech in a research report on Wednesday, December 19th. Finally, ValuEngine upgraded shares of Krystal Biotech from a hold rating to a buy rating in a research report on Monday, February 4th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Krystal Biotech has a consensus rating of Buy and an average price target of $36.90.
Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Tuesday, March 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). As a group, equities research analysts predict that Krystal Biotech will post -1.46 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Knott David M acquired a new stake in Krystal Biotech in the 4th quarter valued at about $31,000. New York State Common Retirement Fund purchased a new stake in Krystal Biotech during the fourth quarter valued at about $159,000. Citigroup Inc. purchased a new stake in Krystal Biotech during the fourth quarter valued at about $214,000. BB&T Securities LLC purchased a new stake in Krystal Biotech during the fourth quarter valued at about $228,000. Finally, Comprehensive Portfolio Management LLC purchased a new stake in Krystal Biotech during the fourth quarter valued at about $299,000. 43.14% of the stock is owned by institutional investors.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.
See Also: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.